Target Populations for Novel Triglyceride-Lowering Therapies
Journal of the American College of Cardiology · 2025-05 · 85 (19) · 1876-1897
DOI: 10.1016/j.jacc.2025.02.035 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of the American College of Cardiology, 2025-05. Verfasst von Ask T Nordestgaard und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cardiovascular Disease Prevention, Division of Preventive Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA; Department o…. Hauptthemen laut MEDLINE: Hypertriglyceridemia, Triglycerides, Hypolipidemic Agents. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 124 Literaturangaben. Gefördert von: Independent Research Fund Denmark.
Abstract (Originalsprache)
Lipoprotein lipase regulates triglyceride hydrolysis and contributes to cellular uptake of triglyceride-rich lipoprotein remnants. Multiple pathways modulate lipoprotein lipase activity, which has prompted interest in the development of drugs that increase lipoprotein lipase activity as means to reduce risk for acute pancreatitis, atherosclerotic cardiovascular disease, and metabolic dysfunction-associated steatohepatitis through reduction of circulating triglycerides and remnant cholesterol. The authors provide an overview of the target populations for agents that lower triglycerides and remnant cholesterol through increased lipoprotein lipase activity, the drugs being developed for these indications, including apolipoprotein C-III and angiopoietin-like protein 3, 3/8, and 4 inhibitors, and the epidemiologic and genetic evidence supporting the use of these drugs for the prevention of atherosclerotic cardiovascular disease and acute pancreatitis. In addition, the authors provide a corresponding overview of fibroblast growth factor-21 analogues that share many characteristics with these novel triglyceride-lowering drugs. Apolipoprotein C-III inhibitors, angiopoietin-like protein 3, 3/8, and 4 inhibitors, and fibroblast growth factor-21 analogues have pronounced triglyceride-lowering and remnant cholesterol-lowering effects. In clinical trials, apolipoprotein C-III inhibitors have been shown to lower risk for acute pancreatitis in patients with severe hypertriglyceridemia and are approved for this indication, while fibroblast growth factor-21 analogues reduce hepatic steatosis and fibrosis in patients with metabolic dysfunction-associated steatohepatitis. It remains to be seen whether these novel drugs may lower risk for atherosclerotic cardiovascular disease as well.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Cardiovascular Disease Prevention, Division of Preventive Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA; Department of Clinical Biochemistry and the Copenhagen General Population Study, C…
- Department of Clinical Biochemistry, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Den…
- 89bio, San Francisco, California, USA.
- Division of Nutritional Sciences, Cornell University, Ithaca, New York, USA.
- Department of Clinical Biochemistry and the Copenhagen General Population Study, Copenhagen University Hospital-Herlev and Gentofte, Herlev, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Scienc…
- Metabolism and Lipids Unit, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Förderung
- Independent Research Fund Denmark
Zitieren
APA
Nordestgaard, A. T., Tybjærg-Hansen, A., Mansbach, H., Kersten, S., Nordestgaard, B. G., & Rosenson, R. S. (2025). Target Populations for Novel Triglyceride-Lowering Therapies. Journal of the American College of Cardiology, 85(19), 1876-1897. https://doi.org/10.1016/j.jacc.2025.02.035
Vancouver
Nordestgaard AT, Tybjærg-Hansen A, Mansbach H, Kersten S, Nordestgaard BG, Rosenson RS. Target Populations for Novel Triglyceride-Lowering Therapies. Journal of the American College of Cardiology. 2025;85(19):1876-1897. doi:10.1016/j.jacc.2025.02.035
BibTeX
@article{Nordestgaard2025,
author = {Nordestgaard, Ask T and Tybjærg-Hansen, Anne and Mansbach, Hank and Kersten, Sander and Nordestgaard, Børge G and Rosenson, Robert S},
title = {Target Populations for Novel Triglyceride-Lowering Therapies},
journal = {Journal of the American College of Cardiology},
year = {2025},
volume = {85},
number = {19},
pages = {1876--1897},
doi = {10.1016/j.jacc.2025.02.035}
}
EUVIMED